157 related articles for article (PubMed ID: 27058567)
1. High-dose cytarabine in mantle cell lymphoma.
Martin P
Clin Adv Hematol Oncol; 2015 Oct; 13(10):646-9. PubMed ID: 27058567
[No Abstract] [Full Text] [Related]
2. Optimal frontline management of mantle cell lymphoma: can we agree?
Tang C; Kuruvilla J
Expert Rev Hematol; 2018 Dec; 11(12):911-914. PubMed ID: 30336708
[No Abstract] [Full Text] [Related]
3. Point: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma: Where It Fits in the New Paradigm.
Goy A
Oncology (Williston Park); 2016 Dec; 30(12):1055-8, 1060. PubMed ID: 27987196
[No Abstract] [Full Text] [Related]
4. [Ten years progression-free survival obtained in a patient with mantle cell lymphoma].
Wysokińska E; Kolak A; Starosławska E; Kieszko D; Kamińska M; Surdyka D; Mocarska A; Burdan F
Pol Merkur Lekarski; 2015 May; 38(227):280-2. PubMed ID: 26039024
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
6. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Klener P; Fronkova E; Belada D; Forsterova K; Pytlik R; Kalinova M; Simkovic M; Salek D; Mocikova H; Prochazka V; Blahovcova P; Janikova A; Markova J; Obr A; Berkova A; Kubinyi J; Vaskova M; Mejstrikova E; Campr V; Jaksa R; Kodet R; Michalova K; Trka J; Trneny M
Hematol Oncol; 2018 Feb; 36(1):110-115. PubMed ID: 29083050
[TBL] [Abstract][Full Text] [Related]
7. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
[TBL] [Abstract][Full Text] [Related]
8. Clinical Management Updates in Mantle Cell Lymphoma.
Chen R; Sanchez J; Rosen ST
Oncology (Williston Park); 2016 Apr; 30(4):353-60. PubMed ID: 27083466
[TBL] [Abstract][Full Text] [Related]
9. Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma.
Pessach I; Petevi K; Gkirkas K; Stamouli M; Constantinou P; Rontogianni D; Dimitriadis G; Tsirigotis P
Leuk Lymphoma; 2016 Nov; 57(11):2702-4. PubMed ID: 26999270
[No Abstract] [Full Text] [Related]
10. Mantle-cell lymphoma in the elderly: is it time to CHOP and change?
Farrell K; Rule S
Leuk Lymphoma; 2012 Oct; 53(10):1855-6. PubMed ID: 22616710
[No Abstract] [Full Text] [Related]
11. Haematological cancer: Bortezomib in MCL--new standard of care or just another option?
Dreyling M
Nat Rev Clin Oncol; 2015 Jul; 12(7):376-8. PubMed ID: 26011491
[No Abstract] [Full Text] [Related]
12. Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model.
Klanova M; Soukup T; Molinsky J; Lateckova L; Vockova P; Alam M; Zivny J; Trneny M; Klener P
Neoplasma; 2016; 63(5):774-8. PubMed ID: 27468882
[TBL] [Abstract][Full Text] [Related]
13. Transplantation for mantle cell lymphoma: is it the right thing to do?
Williams ME
Hematology Am Soc Hematol Educ Program; 2013; 2013():568-74. PubMed ID: 24319233
[TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
15. Late-onset meningeal lymphomatosis in mantle cell lymphoma controlled with chemotherapy.
Alonso JJ; Cánovas A; Riñón MM
Neurologia (Engl Ed); 2018 Apr; 33(3):201-202. PubMed ID: 27126565
[No Abstract] [Full Text] [Related]
16. Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature.
Engman CA; Hill JM; Meehan KR
Clin Adv Hematol Oncol; 2009 May; 7(5):321-3. PubMed ID: 19521320
[No Abstract] [Full Text] [Related]
17. Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma.
Guy D; Kahl BS
Hematol Oncol Clin North Am; 2020 Oct; 34(5):861-870. PubMed ID: 32861283
[TBL] [Abstract][Full Text] [Related]
18. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by
Smith MR; Hong F; Li H; Gordon LI; Gascoyne RD; Paietta EM; Advani RH; Forero-Torres A; Horning SJ; Kahl BS
Leukemia; 2017 Feb; 31(2):517-519. PubMed ID: 27780968
[No Abstract] [Full Text] [Related]
19. Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin.
Anusim N; Gupta A; Howard G; Jaiyesimi I
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509883
[TBL] [Abstract][Full Text] [Related]
20. Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab.
D'Antonio A; Boscaino A; Addesso M; Liguori G; Nappi O
South Med J; 2008 Nov; 101(11):1168-9. PubMed ID: 19088534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
